MAPT and Alzheimer disease: Additionally, there are some abundant tau‐interacting proteins in AKAP9 mutation identified as either pTau interactors in AD (e.g., PSMC5 and PSMD8) or highly enriched in AD NFTs, including CCT3, CCT7, DDX1, EEF2, EZR, PSMA3, and PSMA7 (Drummond et al., 2020).